Duchenne muscular dystrophy (DMD) is an x -linked recessive disorder, primarily characterized by progressive muscle weakness and wasting. The disease results from the absence of dystrophin, however the precise molecular mechanisms leading to muscle pathology are poorly understood. Dystrophic muscles undergo increased oxidative stress and altered calcium homeostasis, which may contribute to myofiber loss by triggering both necrosis and apoptosis. Recent studies have identified ARC (apoptosis repressor with caspase recruitment domain) as an abundant protein in human muscle that can inhibit both hypoxia and caspase-8 induced apoptosis as well as protect cells from oxidative stress. To explore a potential role for ARC in protecting muscle fibers from dystrophic breakdown, we have cloned and characterized murine ARC and studied its expression in normal and dystrophic mouse muscle. ARC is expressed at high levels in striated muscle and displays fiber-type restricted expression patterns.
INTRODUCTION
Duchenne muscular dystrophy is an X-linked recessive, lethal disorder, caused by mutations in the dystrophin gene (1) . DMD affects one in 3,500 newborn males and is characterized by a progressive muscle weakness and wasting, resulting in a wheelchair dependency by the age of 11 and death in the second or third decade from cardiac or respiratory failure (2) . The relationship between the absence of dystrophin and the pathological mechanism of the disease are poorly understood. Dystrophin is thought to play a structural role in providing a link between intracellular actin and extracellular laminin via its interaction with a complex of peripheral and integral membrane proteins, called "the dystrophin-glycoprotein complex" (DGC) (3) . Disruption of this linkage results in membrane instability and dystrophic muscle fibers are highly susceptible to contraction induced injury (4) (5) (6) (7) (8) (9) (10) . Besides providing mechanical stability, several proteins of the DGC play a role in cell signaling (11) (12) (13) (14) (15) (16) . Altered cell signaling is thought to increase the susceptibility of muscle fibers to secondary triggers, such as functional ischemia and oxidative stress (17) (18) (19) (20) (21) . One signaling component of the DGC is the neuronal isoform of nitric oxide synthase (nNOS), which is absent from the sarcolemma in DMD (22) . Muscles from mice deficient in nNOS, as well as dystrophin-deficient mdx muscles, show insufficient production of NO, resulting in impaired metabolic modulation of α-adrenergic vasoconstriction and functional ischemia (17, 18, 23) . Dystrophin -deficient mdx muscles demonstrate oxidative injury prior to muscle pathology, and muscle cells display an increased susceptibility to oxidative stress compared to normal muscles (19, 21) . Reduced NO-mediated cell protection and increased oxidative damage might therefore contribute significantly to the pathology of muscular dystrophy. However, it remains unclear to what extent abnormal DGC-mediated signaling at Pennsylvania State University on February 23, 2013 http://hmg.oxfordjournals.org/ Downloaded from and/or loss of mechanical stability are responsible for the onset and the progression of the disease.
It also remains unclear if muscle fiber breakdown occurs primarily through apoptotic or necrotic processes. Recent studies suggest that cell death in mdx muscle may be initiated by apoptosis and followed by necrotic processes (24) . Tissue sections of dystrophic muscle demonstrate apoptotic myonuclei in degenerating muscle fibers (25) (26) (27) (28) . Several groups proposed that the intensity of the signal, such as intracellular ATP levels, hypoxia and/or reactive oxygen species can dictate whether a cell dies by a primarily necrotic, or an apoptotic, pathway (29) (30) (31) .
The potential contribution of ischemia, oxidative stress and inducers of apoptosis to the dystrophic process are of interest in view of the recent identification of ARC (apoptosis repressor interacting with CARD [caspase recruitment domain]). ARC was identified in the GenBank database using a screen for proteins with homology to the CARD of caspase-9, a key initiator of apoptosis in many cell types (32) . The CARD domain is conserved in numerous proteins and mediates binding to, and regulation of, various caspases (33) (34) (35) . ARC was shown to interact selectively with caspase-2 and caspase-8 via its CARD and to inhibit caspase-8 induced apoptosis (32) . ARC has also been shown to inhibit both hypoxia induced, and hydrogen peroxidase mediated, cell death in H9C2 cells and to protect the heart from postischemic cardiomyopathy (36) (37) (38) (39) (40) . Intriguingly, ARC expression in humans is restricted pri marily to striated muscles, tissues that do not normally undergo rapid cell turnover or apoptosis (32) . This high level expression of an apoptosis inhibitor in long-lived cell types raises the possibility that ARC could help protect muscle fibers from apoptotic death resulting from mechanical stress or oxidative damage. Since myofiber death in dystrophic muscles has been linked to increased oxidative stress, ischemia and mechanical injury, we sought to study the expression of ARC in a Isolation of mouse ARC cDNA. The full-length mouse ARC cDNA was isolated by direct PCR amplification from a muscle cDNA library (41) using primers derived from an EST clone (accession number AA596110) and vector specific primers. Direct sequencing of PCR products revealed that the longest open reading frame encoded a protein of 220 amino acids with a predicted molecular mass of 24.5 kDa (GenBank accession no. AY459322). The protein sequence displayed 80% identity to the previously identified human ARC (32) and 91% identity to the rat ortholog (42)(data not shown).
Alignment analysis confirmed that mouse ARC contains a N-terminal CARD and a C-terminal proline/glutamic acid-rich (P/E) domain. The CARD domain of ARC has significant amino acid similarity to the CARD domains from caspase-2, caspase-9, RAIDD and APAF-1 (32) and is structurally related to the death effector domain (DED) shared by effector caspases (35) .
The human ARC gene has been reported to encode two proteins that differ by alternative RNA splicing. The alternative product has been named nucleolar protein Nop30 and has been shown to interact with the splicing factor SRp30c (43). Nop30 contains a 10 bp deletion that leads to a frame shift between amino acids 95 and 96, resulting in a different C-terminal domain consisting of 124 amino acids (43) . To determine whether the mouse ARC gene also encoded a Nop30 like protein we amplified ARC from a mouse muscle cDNA library and subcloned the PCR product. Ten independent clones were sequenced and all encoded the normal, full-length ARC. Furthermore, we digested the PCR product with PmlI, which cuts within the 10 bp deletion of the potential Nop30 cDNA and would distinguish between ARC and Nop30. We were able to detect the ARC cDNA, but less than 5% of the product remained undigested (data not shown (Fig. 1A ).
ARC expression in mice.
To examine ARC gene expression in mice we initially probed a multiple tissue northern blot. Mouse ARC was highly expressed in heart, and at a slightly lower level in skeletal muscle (Fig.1B) . Some ARC expression was detected in brain and testis, with very low levels in kidney and lung. No ARC expression was detected in liver or spleen.
Interestingly, in testis ARC mRNA was expressed as a longer transcript than in other tissues possibly due to an alternative polyadenylation site as seen in human tissue (43) . The nature of the larger transcript in heart is unclear and could be the result of alternative splicing or polyadenylation site usage. This expression agrees with the reported ARC mRNA expression pattern in human and rat tissues (32, 42) . As the mdx mouse represents a good model for myofiber breakdown and turnover, we asked if ARC displayed a different expression pattern in dystrophic muscle. We compared ARC protein levels in C57BL/10J and mdx mouse skeletal muscles at 2 and 6 months of age via western blotting. ARC was found to be expressed at essentially the same levels in C57BL/10J and mdx muscles at both ages ( Fig. 2A) .
Co-localization of ARC with mitochondria. To examine the localization of ARC in muscle fibers, we immuno-stained serial frozen sections of C57BL/10J and mdx mice for ARC (Fig.   2B ). ARC staining showed a non-uniform expression pattern across the muscle section, suggesting that ARC was expressed in a fiber-type specific manner. This pattern was observed in diaphragm, quadriceps and tibialis anterior muscles, while the expression in heart showed a uniform expression pattern (data not shown). ARC was expressed at similar levels in wild-type and mdx animals in these muscle types and appeared to be predominantly cytoplasmic.
Hypercontracted myofibers in mdx muscle demonstrated a shift of ARC to the sarcolemma (data not shown). ARC expression in C57 muscle showed a distinct regular pattern of ARC positive and negative fibers, while ARC expression in the mdx background appeared as a less distinct and more irregular pattern. To determine if ARC expression is fiber type specific, we co-stained for ARC and for the mitochondrial-specific protein cytochrome oxidase. Cytochrome oxidase is mainly restricted to oxidative fibers, which display an oxidative metabolism and contain numerous mitochondria (44) . ARC co-localized with cytochrome oxidase, showing that ARC is expressed mainly in oxidative fibers and that it is co-localized with mitochondria within the muscle fiber (Fig. 2B ).
Transgenic ARC expression & localization.
We generated transgenic mice in order to test the hypothesis that forced overexpression of ARC might maintain myofiber survival and alleviate the dystrophic muscle pathology of mdx mice (Fig. 3A) . Transgenic ARC expression was analyzed in C57BL/10J and mdx mice and expression levels were compared with endogenous ARC levels ( Fig. 3B ).
Western analysis showed that the transgene was highly expressed in quadriceps and diaphragm muscle on both the C57Bl/10J and the mdx background. Immunohistochemical analysis revealed that the transgene was uniformly expressed in quadriceps and diaphragm muscle and that it localized predominantly to the sarcoplasm in C57BL/10J muscle and shifted towards the sarcolemma in the mutant mdx background (Fig. 3C ). Immunohistochemical analysis of soleus and heart muscle showed a mosaic overexpression pattern in soleus, while expression in heart muscle was observed only in rare myocytes (Fig. 4C ). This latter observation is consistent with our previous results showing that the HSA expression cassette used in this study is generally not active in cardiac muscle (10, 45, 46) .
To examine whether transgenic ARC co-localized with mitochondria, we co-stained transgenic quadriceps muscle sections for ARC and for the mitochondrial marker cytochrome oxidase ( Caspase-3 activity and membrane permeability in mdx and ARC transgenic/mdx mice.
ARC has been suggested to act as an inhibitor of apoptotic cell death by preventing activation of caspase-8 and caspase-2 (32) . To compare the level of apoptosis in C57BL/10J, mdx and transgenic/mdx muscle we analyzed active caspase-3 expression by immunofluorescence (Fig.   5 ). Caspase-3 represents the key effector caspase and is therefore a good indicator for cells undergoing apoptosis. Previously, TUNEL positive fibers were detected in mdx mice by several groups, suggesting the presence of a low level of apoptosis (24, 25, 27, 47) . mdx and transgenic/mdx muscle showed a number of caspase-3 positive fibers, the vast majority of which appeared necrotic by hematoxylin and eosin staining. No obvious differ ences could be detected between mdx and transgenic/mdx skeletal muscles. No active caspase-3 staining was observed in C57BL/10J muscles.
Evans blue dye is commonly used as a marker to distinguish degenerating and intact muscle fibers (7) . Consequently, we analyzed Evans blue uptake in mdx and Tg ARC/mdx mice.
mdx as well as ARC transgenic/mdx mice displayed a large and variable number of Evans blue positive myofibers, the majority of which appeared to be necrotic. We did not observe an obvious difference in Evans blue uptake between mdx and Tg ARC/mdx muscle (Fig. 5) . We compared Evans blue localization with active caspase-3 localization to address the possibility that caspase-3 activation might be a consequence of membrane damage. Interestingly, all active caspase-3 positive fibers were also positive for Evans blue, but not all Evans blue positive fibers stained positively for activated caspase-3 (Fig. 5) . Muscle fibers that showed co-localization of Evans blue and caspase-3, however, showed different distribution patterns and intensity levels of Localization of caspase-3 and ARC. We co-stained serial sections from quadriceps muscle of transgenic/mdx mice for active caspase-3 and ARC to compare their expression and localization pattern in muscle fibers (Fig. 6) . Interestingly, caspase-3 positive fibers displayed faint or no ARC staining, suggesting that ARC is downregulated or degraded in these fibers.
Downregulation could be a consequence of altered signaling and apoptosis in mdx muscle, while degradation could be a consequence of muscle fiber necrosis.
DISCUSSION
Much progress has been made over the last decade in understanding the genetic and biochemical features of dystrophin and the DGC. However, little is known about the pathogenic mechanisms leading to the onset of muscular dystrophy and to progression of the disease. Several members of the DGC are associated with signaling molecules that provide a link to crucial signal transduction pathways (12) (13) (14) (15) (16) . Disruption of these signaling cascades could alter metabolic pathways leading to increased susceptibility to oxidative stress, elevated calcium levels, altered mitochondrial function and eventually to apoptotic or necrotic cell death. (19, 21, 24, 25, (48) (49) (50) (51) .
Several groups have characterized the expression of proteins involved in apoptosis in normal and diseased skeletal muscle tissue (28, (52) (53) (54) . Most apoptotic proteins are expressed at a low or non-detectable level in normal mice and demonstrate elevated expression only in degenerating and regenerating muscle fibers of mdx mice (28, 55) . We cloned the mouse isoform of the anti-apoptotic protein ARC and characterized its expression pattern in mice. ARC is the only anti-apoptotic protein known to be expressed at high levels in skeletal muscle (32) . Interestingly, human ARC was shown to have an alternative splice product, named
Nop30, that interacts with the splicing factor SRp30c (43). We were not able to find any evidence that Nop30 is expressed in mouse muscle. Our data is supported by the expression profile of SRp30c, which, in contrast to human muscle, is expressed at very low levels in mouse skeletal muscle (59) . This lack of alternative splicing of the ARC gene in mouse skeletal muscle demonstrates one example of evolutionary divergence between humans and mice.
We characterized endogenous ARC expression in normal and mdx mice to explore the effect of a dystrophic background on ARC expression. ARC expression levels are similar in normal and mdx muscle. However, ARC localization is altered in the mdx background. Altered mitochondrial protein expression and localization could be responsible for differences in intracellular ARC localization in the C57BL/10J and mdx background. It was previously shown that respiratory chain-linked enzymes were downregulated in mdx muscle and oxidative phosphorylation was altered compared to normal muscle (49, 51, 60, 61) . To test if elevated levels of the anti-apoptotic and hypoxia-protecting protein ARC might alleviate any dystrophic phenotypic features, we generated transgenic mice that overexpressed ARC. Endogenous ARC was expressed at high levels in skeletal muscle, but mainly in oxidative fibers. We explore whether overexpression of ARC in all fiber types might protect dystrophic myofibers from apoptotic and/or necrotic cell death. Transgenic ARC was expressed uniformly in all fiber types and colocalized with mitochondria in oxidative fibers. To examine muscle fiber breakdown, we analyzed Evans blue uptake and active caspase-3 expression in transgenic ARC/mdx and mdx muscle. We found Evans Blue uptake and active caspase-3 positive fibers in transgenic ARC/mdx and mdx muscle fibers, the majority of which appeared to be at various stages of Although it has been shown in previous studies that apoptosis plays a role in dystrophic pathology, it remains unclear if apoptosis causes or is a secondary effect of muscle fiber breakdown (25, 62) . We detected active caspase -3 in dystrophic muscle, but the majority of the fibers appeared to be necrotic and had lost their membrane integrity, which would argue in favor of apoptosis being a secondary consequence resulting from loss of muscle fiber integrity.
However, not all Evans blue positive fibers displayed clear staining for active caspase-3, and the intensity level and staining pattern within individual myofibers was variable, indicating that muscle fibers were at various stages of degeneration. These observations reinforce the idea that muscle cell death is a dynamic process and may reflect the increased susceptibility of myofibers to secondary triggers resulting from altered cell signaling, leading to active cell death.
Interestingly, while we were able to detect some relatively normal appearing Evans blue dye positive myofibers that did not express caspase-3, all caspase-3 positive fibers were at least weakly positive for Evans blue dye. These observations suggest a sequence of molecular events in dystrophic muscle in which an initial membrane damaging event allows the uptake of large extracellular molecules such as Evans blue dye, which is subsequently followed by upregulation of caspase-3 and loss of ARC expression. Although apoptosis and necrosis represent different mechanism of cell death, both may be intertwined. The ultimate fate of a cell may depend on the relative intensity of the secondary triggers and the energy status of the cell (29-31).
Nonetheless, we were not able to determine from these studies whether ARC overexpression failed to inhibit apoptosis in mdx muscles, or whether the apoptotic pathways regulated by ARC do not contribute to the dystrophic phenotype in mdx mice. The multiple functions of dystrophin and the DGC make it difficult to determine the extent that signaling failures contribute to muscle fiber death in mdx muscles. However, it was shown that altered signaling leads to impaired modulation of α-adrenergic vasoconstriction and functional ischemia in dystrophic muscle (17) . While over-expression of ARC in the heart has been shown to protect from myocardial ischemia, over-expression of ARC in mdx skeletal muscles clearly did not alter the dystrophic phenotype (39, 40) . This observation could be explained by the fact that the dystrophic pathology results from alterations in multiple molecular pathways that together contribute to muscle fiber death. While the restoration of one signaling pathway may not be sufficient to ameliorate dystrophic pathology, a combination of treatments targeting mechanical, immunological and signaling pathways might be more effective (6, 16, 17, 20, 49, 63, 64) . Evans blue Assay. Evans blue dye (10 mg/ml in PBS) was injected into the tail vein of 6 week old mdx, transgenic/mdx and C57BL/10J mice (50 µl/10 g body weight). After 3 hours, mice were euthanized and quadriceps muscle were frozen in liquid nitrogen cooled O.C.T. embedding media. Frozen, 5µm thick sections were analyzed for Evans Blue uptake by fluorescence microscopy (7). at Pennsylvania State University on February 23, 2013 
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Isolation
